#ASH17: Verastem's AbbVie castoff is headed for the FDA — even after missing overall survival goal
When Verastem $VSTM CEO Robert Forrester highlighted the positive endpoint from the pivotal study of duvelisib a few months ago, he didn’t want to talk about the secondary data points. That, he said, was being saved for a future scientific conference.
And today at ASH you can see the added data isn’t something you’d want to discuss much.
The drug — which hit statistical significance on progression-free survival — flunked the key overall survival secondary, failing to do any better than Arzerra (ofatumumab) in extending the lives of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.